UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 10-Q
(Mark One)
| [X] |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| For the quarterly period ended: March 31, 2003 |
| [ ] |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| For the transition period from to |
Commission File Number: 0-11647
HYCOR BIOMEDICAL INC.
| Delaware | 58-1437178 | |
|
|
||
| (State or other jurisdiction of incorporation or organization) |
(I. R. S. Employer Identification No.) |
7272 Chapman Avenue, Garden Grove, California 92841
Registrants telephone number, including area code (714) 933-3000
No Change
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant is an accelerated filer (as identified in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]
Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date.
| Class | Outstanding at April 18, 2003 | |
|
|
||
| Common Stock, $.01 Par Value | 8,062,193 |
PART I. FINANCIAL INFORMATION
ITEM I. FINANCIAL STATEMENTS
HYCOR BIOMEDICAL INC. AND SUBSIDIARI ES
CONSOLIDATED BALANCE SHEETS
(unaudited)
| March 31, | December 31, | |||||||||||
| 2003 | 2002 | |||||||||||
ASSETS |
||||||||||||
CURRENT ASSETS: |
||||||||||||
Cash and cash equivalents |
$ | 1,349,151 | $ | 1,667,181 | ||||||||
Investments |
3,832,249 | 3,791,188 | ||||||||||
Accounts receivable, net of allowance for
doubtful accounts of $96,575 (2003) and $90,598 (2002) |
2,623,628 | 2,785,556 | ||||||||||
Inventories |
4,876,580 | 5,241,984 | ||||||||||
Prepaid expenses and other current assets |
274,152 | 286,268 | ||||||||||
Total current assets |
12,955,760 | 13,772,177 | ||||||||||
PROPERTY AND EQUIPMENT, at cost |
10,066,271 | 9,895,589 | ||||||||||
Less accumulated depreciation and amortization |
(7,881,735 | ) | (7,617,573 | ) | ||||||||
Property and equipment, net |
2,184,536 | 2,278,016 | ||||||||||
GOODWILL |
156,338 | 156,338 | ||||||||||
INTANGIBLES AND OTHER ASSETS, net of
Accumulated amortization of $156,825 (2003) and $154,660 (2002) |
86,228 | 88,392 | ||||||||||
Total assets |
$ | 15,382,862 | $ | 16,294,923 | ||||||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||||||
CURRENT LIABILITIES: |
||||||||||||
Accounts payable |
$ | 568,939 | $ | 461,317 | ||||||||
Accrued liabilities |
612,353 | 678,196 | ||||||||||
Accrued payroll expenses |
550,247 | 890,349 | ||||||||||
Current portion of long-term debt |
| 2,028 | ||||||||||
Total current liabilities |
1,731,539 | 2,031,890 | ||||||||||
Long-term debt, net of current portion |
| 1,000,000 | ||||||||||
Total Liabilities |
1,731,539 | 3,031,890 | ||||||||||
STOCKHOLDERS EQUITY: |
||||||||||||
Common stock |
80,622 | 80,491 | ||||||||||
Paid-in capital |
12,931,758 | 12,908,133 | ||||||||||
Retained earnings |
1,240,630 | 909,492 | ||||||||||
Accumulated other comprehensive loss |
(601,687 | ) | (635,083 | ) | ||||||||
Total stockholders equity |
13,651,323 | 13,263,033 | ||||||||||
Total liabilities and stockholders equity |
$ | 15,382,862 | $ | 16,294,923 | ||||||||
Page 2
HYCOR BIOMEDICAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(unaudited)
| Three Months Ended | |||||||||||
| March 31, | |||||||||||
| 2003 | 2002 | ||||||||||
NET SALES |
$ | 4,877,566 | $ | 4,571,509 | |||||||
COST OF SALES |
2,332,717 | 2,225,037 | |||||||||
Gross profit |
2,544,849 | 2,346,472 | |||||||||
OPERATING EXPENSES: |
|||||||||||
Selling, general, and administrative |
1,707,935 | 1,483,951 | |||||||||
Research and development |
542,641 | 584,533 | |||||||||
Total operating expenses |
2,250,576 | 2,068,484 | |||||||||
OPERATING INCOME |
294,273 | 277,988 | |||||||||
INTEREST EXPENSE |
(3,231 | ) | (10,475 | ) | |||||||
INTEREST INCOME |
46,848 | 33,045 | |||||||||
GAIN (LOSS) ON FOREIGN CURRENCY TRANSACTIONS |
36,648 | (4,230 | ) | ||||||||
INCOME BEFORE INCOME TAX PROVISION |
374,538 | 296,328 | |||||||||
INCOME TAX PROVISION |
43,400 | 43,744 | |||||||||
NET INCOME |
$ | 331,138 | $ | 252,584 | |||||||
BASIC EARNINGS PER SHARE |
$ | 0.04 | $ | 0.03 | |||||||
DILUTED EARNINGS PER SHARE |
$ | 0.04 | $ | 0.03 | |||||||
AVERAGE COMMON SHARES OUTSTANDING: |
|||||||||||
Basic |
8,049,068 | 8,024,687 | |||||||||
Diluted |
8,160,998 | 8,229,876 | |||||||||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME |
|||||||||||
NET INCOME |
$ | 331,138 | $ | 252,584 | |||||||
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX |
|||||||||||
Foreign currency translation adjustments |
14,260 | (56,461 | ) | ||||||||
Unrealized gains (losses) on securities |
19,401 | (56,382 | ) | ||||||||
Plus: reclassification adjustment for (gains) losses included in net income |
(265 | ) | 4,192 | ||||||||
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX |
33,396 | (108,651 | ) | ||||||||
COMPREHENSIVE INCOME |
$ | 364,534 | $ | 143,933 | |||||||
Page 3
HYCOR BIOMEDICAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
| Three Months Ended | ||||||||||||
| March 31, | ||||||||||||
| 2003 | 2002 | |||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||||||
Net income |
$ | 331,138 | $ | 252,584 | ||||||||
Adjustments to reconcile net income to net cash provided by
operating activities: |
||||||||||||
Depreciation and amortization |
223,683 | 225,043 | ||||||||||
Provision for doubtful accounts receivable |
12,271 | 5,413 | ||||||||||
Provision for excess and obsolete inventories |
113,373 | 122,490 | ||||||||||
(Gain) Loss on sales of investments |
(312 | ) | 4,521 | |||||||||
Change in assets and liabilities, net of effects of foreign currency adjustments |
||||||||||||
Accounts receivable |
169,786 | (104,108 | ) | |||||||||
Inventories |
277,418 | 229,198 | ||||||||||
Prepaid expenses and other current assets |
2,285 | (87,406 | ) | |||||||||
Accounts payable |
107,260 | (16,881 | ) | |||||||||
Accrued liabilities |
(68,387 | ) | 68,044 | |||||||||
Accrued payroll expenses |
(341,180 | ) | (194,522 | ) | ||||||||
Total adjustments |
496,197 | 251,792 | ||||||||||
Net cash provided by operating activities |
827,335 | 504,376 | ||||||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||||||
Purchases of investments |
(42,145 | ) | (298,700 | ) | ||||||||
Proceeds from sales of investments |
20,030 | 276,895 | ||||||||||
Purchases of property and equipment |
(107,881 | ) | (153,723 | ) | ||||||||
Other |
| (453 | ) | |||||||||
Net cash used in investing activities |
(129,996 | ) | (175,981 | ) | ||||||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||||||
Principal payments on long-term debt |
(1,002,028 | ) | (10,285 | ) | ||||||||
Proceeds from issuance of common stock |
23,756 | 17,484 | ||||||||||
Net cash (used in) provided by financing activities |
(978,272 | ) | 7,199 | |||||||||
EFFECT OF EXCHANGE RATE CHANGES ON CASH |
(37,097 | ) | (10,887 | ) | ||||||||
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS |
(318,030 | ) | 324,707 | |||||||||
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
1,667,181 | 1,354,334 | ||||||||||
CASH AND CASH EQUIVALENTS, END OF PERIOD |
$ | 1,349,151 | $ | 1,679,041 | ||||||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION- |
||||||||||||
Cash paid during the period interest |
$ | 3,224 | $ | 10,596 | ||||||||
- income taxes |
$ | 3,535 | $ | 30,383 | ||||||||
Page 4
HYCOR BIOMEDICAL INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2003
1. Basis of Presentation
| In the opinion of the Company, the accompanying unaudited consolidated financial statements include all adjustments necessary to present fairly the financial position of the Company as of March 31, 2003 and December 31, 2002, the results of its operations and the cash flows for the three-month periods ended March 31, 2003 and 2002. |
| These statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission and do not include all the information and note disclosures required by accounting principles generally accepted in the United States of America for complete financial statements but reflect all adjustments (consisting only of normal recurring accruals) necessary for the fair presentation of the financial position, results of operations and cash flows for the periods and dates presented. |
| These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Companys 2002 annual report on Form 10-K as filed with the Securities and Exchange Commission. Certain items in the 2002 consolidated financial statements have been reclassified to conform to the 2003 presentation. |
| The results of operations for any interim period are not necessarily indicative of results to be expected for the full year. |
| Basic earnings per share is computed by dividing net income by the weighted-average number of shares outstanding, while diluted EPS additionally includes the dilutive effect of the Companys outstanding options and warrants computed using the treasury stock method. |
2. Accounting for Stock-Based Compensation
| The Company accounts for its employee stock-based awards using the intrinsic value method in accordance with APB Opinion No. 25, and its related interpretations. |
| SFAS No. 123, Accounting for Stock-Based Compensation, requires the disclosure of pro forma net income (loss) and net income (loss) per share had the Company adopted the fair value method. Under SFAS No. 123, the fair value of stock-based awards to employees is calculated through the use of option pricing models, even though such models were developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which significantly differ from the Companys stock option awards. If the computed fair values of the 2003 and 2002, stock awards had been amortized to expense over the vesting period of the awards, pro forma net income would have been as follows: |
Page 5
| Three Months Ended | |||||||||
| March 31, | March 31, | ||||||||
| 2003 | 2002 | ||||||||
Net Income: |
|||||||||
Net income, as reported |
$ | 331,138 | $ | 252,584 | |||||
Less: Total stock based employee
compensation expense determined
under fair value based method for
all awards, net of related tax effects |
(52,119 | ) | (31,754 | ) | |||||
Pro forma net income |
$ | 279,019 | $ | 220,830 | |||||
Earnings per Common Share: |
|||||||||
Basic as reported |
$ | 0.04 | $ | 0.03 | |||||
Basic pro forma |
$ | 0.03 | $ | 0.03 | |||||
Diluted as reported |
$ | 0.04 | $ | 0.03 | |||||
Diluted pro forma |
$ | 0.03 | $ | 0.03 | |||||
3. Inventories
| Inventories are valued at the lower of cost (first-in, first-out method) or market. Cost includes material, direct labor, and manufacturing overhead. Inventories at March 31, 2003 and December 31, 2002 consist of: |
| 3/31/03 | 12/31/02 | |||||||
Raw materials |
$ | 1,107,536 | $ | 1,232,950 | ||||
Work in process |
2,057,984 | 2,109,407 | ||||||
Finished goods |
1,711,060 | 1,899,627 | ||||||
| $ | 4,876,580 | $ | 5,241,984 | |||||
4. Long Term Debt
| The Company has available a $2,000,000 line of credit with a maturity date of July 1, 2004. Advances under the line of credit are collateralized by the Companys accounts receivable, inventories, and property and equipment and bear interest at the prime rate or at LIBOR plus 2%. |
| The line of credit contains restrictive covenants, the most significant of which relate to the maintenance of minimum tangible net worth, debt-to-tangible net worth requirements, and liquid assets plus accounts receivable-to-current liabilities requirements. During the quarter ended March 31, 2003, the Company paid the outstanding balance of $1,000,000 on this line of credit. |
5. Indemnification and Guarantees
| The Company has entered into employment contracts with each of the Companys officers. These contracts generally provide for severance benefits if the officer is terminated by the Company for convenience or by the officer for substantial cause. In addition, in order to assure that the officers would continue to provide independent leadership consistent with the Companys |
Page 6
| best interests in the event of an actual or threatened change in control of the Company, the contracts also generally provide for certain protections in the event of such a change in control. These protections include the extension of employment contracts and the payment of certain severance benefits upon the termination of employment following a change in control. |
6. New Accounting Pronouncements
| In November 2002, the FASB issued FASB Interpretation No. 45 (FIN 45), Guarantors Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees and Indebtedness of Others. FIN 45 elaborates on the disclosures to be made by the guarantor in its interim and annual financial statements about its obligations under certain guarantees that it has issued. It also requires that a guarantor recognize, at the inception of a guarantee, a liability for the fair value of the obligation undertaken in issuing the guarantee. The initial recognition and measurement provisions of this interpretation are applicable on a prospective basis to guarantees issued or modified after December 31, 2002; while the provisions of the disclosure requirements are effective for financial statements of interim or annual reports ending after December 15, 2002. The Company has adopted the provisions of FIN 45 as of January 1, 2003 and such adoption did not have a material impact on its consolidated financial statements. |
| In January 2003, the FASB issued FASB Interpretation No. 46 (FIN 46), Consolidation of Variable Interest Entities. In general, a variable interest entity is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. FIN 46 requires certain variable interest entities to be consolidated by the primary beneficiary of the entity if the entity investors in the entity do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. The consolidation requirements of FIN 46 apply immediately to variable interest entities created after January 31, 2003. The consolidation requirements apply to older entities in the first fiscal year or interim period beginning after June 15, 2003. Certain of the disclosure requirements apply in all financial statements issued after January 31, 2003, regardless of when the variable interest entity was established. The Company expects that the provisions of FIN 46 will not have a material impact on its consolidated financial statements since the Company currently has no variable interest entities. |
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
General
Page 7
contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such factors include, but are not limited to, product demand and market acceptance risks; the effect of economic conditions; the impact of competitive products and pricing; product development; commercialization and technological difficulties; capacity and supply constraints or difficulties; difficulties competing against larger companies which have substantially greater financial resources; failure to receive and maintain regulatory approvals for our products; rapid technological change and new products developed by others which are more effective or less costly than our current or future products or which render our technologies and products obsolete or non-competitive; availability of capital resources; general business and economic conditions, including currency risks based on the relative strength or weakness of the U.S. dollar, euro conversions, and changes in government laws and regulations, including taxes; and the other risks and uncertainties described in the Companys filings with the Securities and Exchange Commission. The historical results achieved by the Company are not necessarily indicative of its future prospects. The Company undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
Significant Accounting Policies
Revenue Recognition
Accounts Receivable
Page 8
Inventories
Additionally, the Companys manufacturing costs and inventory carrying costs are dependent on managements accurate estimates of customer demand for the Companys products. A significant increase in the demand for the Companys products could result in a short-term increase in the cost of inventory purchases, while a significant decrease in demand could result in an increase in the amount of excess inventory quantities on hand and increase the expense of storing and maintaining the inventory until it is sold. Therefore, although management makes every effort to ensure the accuracy of its forecasts of future product demand, any significant unanticipated changes in demand or technological developments could have a significant impact on the value of the Companys inventory and its reported operating results.
Deferred Taxes
Warranties
Page 9
New Accounting Pronouncements
Financial Condition and Liquidity
During the three-month periods ended March 31, 2003 and 2002, total capital expenditures were approximately $108,000 and $154,000, respectively. Capital spending during the three-month periods ended March 31, 2003 and 2002 included approximately $5,000 and $105,000 for reagent rental equipment and $65,000 and $21,000 for tooling and test equipment utilized in the Companys manufacturing and research and development areas, respectively. For fiscal 2003, the Company currently anticipates capital spending on property and equipment to be in the range of $500,000 to $600,000.
The Companys principle capital commitments are for lease payments under non-cancelable operating leases. Additionally, the HY-TEC business requires the purchase of instruments, which in many cases are placed in use in laboratories of the Companys direct customers and paid for over an agreed contract period through the purchase of test reagents. This reagent rental sales program, common to the diagnostic market, creates negative cash flows in the initial years. The Company has entered into a long-term product manufacturing and sales agreement (the Supply Agreement) with an equipment manufacturer located in Europe. The Supply Agreement provides for the European manufacturer to supply and the Company to purchase certain minimum levels of HY-TEC instruments.
In addition, in the normal course of operations, the Company enters into purchase obligations with various vendors and suppliers of various key raw materials and other goods and services through purchase orders or other documentation. Such obligations are generally outstanding for periods less than a year and are settled by cash payments upon delivery of goods and services. The purchase commitments covered by these various key raw materials and other goods and services aggregate approximately $1,033,000 for 2003.
The following table summarizes the approximate future minimum payments under the above contractual obligations for the twelve-month periods as from March 31, 2003:
| Payment Due by Period | ||||||||||||||||||||
| Less than | 13 | 45 | After 5 | |||||||||||||||||
| Capital Commitments | Total | 1 Year | Years | Years | Years | |||||||||||||||
Operating Leases |
$ | 3,207,000 | $ | 784,000 | $ | 1,431,000 | $ | 992,000 | | |||||||||||
The Supply Agreement |
231,000 | 231,000 | | | | |||||||||||||||
Other Purchase Commitments |
1,033,000 | 1,033,000 | ||||||||||||||||||